Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0300)
Name
XAV939
Synonyms
284028-89-3; XAV-939; XAV939; 3,5,7,8-Tetrahydro-2-[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidin-4-one; XAV 939; 2-[4-(trifluoromethyl)phenyl]-1,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidin-4-one; CHEBI:62878; CHEMBL1086580; XAV-939 (GMP); CID 2726824; 2-(4-(trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-4-ol; 2-[4-(trifluoromethyl)phenyl]-7,8-dihydro-5H-thiino[4,3-d]pyrimidin-4-ol; 2-[4-(Trifluoromethyl)phenyl]-7,8-Dihydro-5h-Thiopyrano[4,3-D]pyrimidin-4-Ol; NVP-XAV-939; 2-(4-(trifluoromethyl)phenyl)-7,8-dihydro-3H-thiopyrano[4,3-d]pyrimidin-4(5H)-one; C14H11F3N2OS; XAV; MFCD16879017; 3kr8; 3uh4; Maybridge3_005018; NVP-XAV939; MLS006012021; SCHEMBL7783488; TB3748-GMP; SCHEMBL15315468; DTXSID60369423; XAV939,XAV-939; BCPP000009; HMS1445E02; HMS3414D07; HMS3648B17; HMS3654O16; HMS3678D07; HMS3743E05; BCP02128; EX-A1760; BDBM50188594; BDBM50318567; HB0660; HY-15147G; NSC755761; s1180; 2-[4-(trifluoromethyl)phenyl]-5H,7H,8H-thiopyrano[4,3-d]pyrimidin-4-ol; AKOS015954858; AKOS024457786; AKOS026750243; CCG-208105; CS-0494; NSC-755761; SB19432; IDI1_016405; NCGC00250397-01; NCGC00484998-01; AC-28393; CS-10386; HY-15147; SMR003874205; XAV939, >=98% (HPLC); CS-0615627; FT-0675873; SW218311-2; X0077; A25698; EN300-6732792; SR-01000946403; J-511234; SR-01000946403-1; BRD-K12762134-001-01-3; BRD-K12762134-001-05-4; Q27132250; Z2235801832; 2-(4-(Trifluoromethyl)phenyl)-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one; 2-(4-(trifluoromethyl)phenyl)-7,8-dihydro-1H-thiopyrano[4,3-d]pyrimidin-4(5H)-one; 2-(4-(Trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano-[4,3-d]pyrimidin-4-ol; 2-[4-(trifluoromethyl)phenyl]-1H,4H,5H,7H,8H-thiopyrano[4,3-d]pyrimidin-4-one; 4H-Thiopyrano[4,3-d]pyrimidin-4-one, 3,5,7,8-tetrahydro-2-[4-(trifluoromethyl)phenyl]-?

    Click to Show/Hide
Status
Preclinical
Drug Type
Small molecular drug
Structure
Formula
C14H11F3N2OS
IUPAC Name
2-[4-(trifluoromethyl)phenyl]-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidin-4-one
Canonical SMILES
C1CSCC2=C1N=C(NC2=O)C3=CC=C(C=C3)C(F)(F)F
InChI
InChI=1S/C14H11F3N2OS/c15-14(16,17)9-3-1-8(2-4-9)12-18-11-5-6-21-7-10(11)13(20)19-12/h1-4H,5-7H2,(H,18,19,20)
InChIKey
KLGQSVMIPOVQAX-UHFFFAOYSA-N
PubChem CID
135418940
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 3 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Lung cancer ICD-11: 2C25
 Disease Info 
Responsed Regulator Transcription factor SOX-4 (SOX4) Suppressor
 Regulator Info 
Pathway Response Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell proliferation
Cell apoptosis
In Vitro Model NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
Response regulation The downregulation of the lncRNA MIR503HG induced by XAV939 may serve an important role in suppressing the progression of non-small cell lung cancer via sponging miR1273c, to downregulate its target SOX4. Furthermore, the downregulation of SLC7A11 induced by XAV939 may inhibit NSCLC development via participation in the ferroptosis pathway.
Experiment 2 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Lung cancer ICD-11: 2C25
 Disease Info 
Responsed Regulator hsa-miR-1273c (miRNA) Driver
 Regulator Info 
Pathway Response Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell proliferation
Cell apoptosis
In Vitro Model NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
Response regulation The downregulation of the lncRNA MIR503HG induced by XAV939 may serve an important role in suppressing the progression of non-small cell lung cancer via sponging miR1273c, to downregulate its target SOX4. Furthermore, the downregulation of SLC7A11 induced by XAV939 may inhibit NSCLC development via participation in the ferroptosis pathway.
Experiment 3 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Lung cancer ICD-11: 2C25
 Disease Info 
Responsed Regulator MIR503HG (IncRNA) Suppressor
 Regulator Info 
Pathway Response Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell proliferation
Cell apoptosis
In Vitro Model NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
Response regulation The downregulation of the lncRNA MIR503HG induced by XAV939 may serve an important role in suppressing the progression of non-small cell lung cancer via sponging miR1273c, to downregulate its target SOX4. Furthermore, the downregulation of SLC7A11 induced by XAV939 may inhibit NSCLC development via participation in the ferroptosis pathway.
Cystine/glutamate transporter (SLC7A11)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Lung cancer ICD-11: 2C25
 Disease Info 
Pathway Response Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell proliferation
Cell apoptosis
In Vitro Model NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
Response regulation The downregulation of the lncRNA MIR503HG induced by XAV939 may serve an important role in suppressing the progression of non-small cell lung cancer via sponging miR1273c, to downregulate its target SOX4. Furthermore, the downregulation of SLC7A11 induced by XAV939 may inhibit NSCLC development via participation in the ferroptosis pathway.
References
Ref 1 RNA sequencing uncovers the key long non-coding RNAs and potential molecular mechanism contributing to XAV939-mediated inhibition of non-small cell lung cancer. Oncol Lett. 2019 Jun;17(6):4994-5004. doi: 10.3892/ol.2019.10191. Epub 2019 Mar 27.